Clinical Trials Logo

Acromegaly clinical trials

View clinical trials related to Acromegaly.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05364944 Active, not recruiting - Acromegaly Clinical Trials

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

OXTEND-01
Start date: May 18, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label, single treatment arm, multicenter study to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Debio 4126 in the treatment of participants with Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine tumors (GEP-NETs).

NCT ID: NCT05192382 Active, not recruiting - Acromegaly Clinical Trials

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)

PATHFNDR-2
Start date: December 17, 2021
Phase: Phase 3
Study type: Interventional

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly.

NCT ID: NCT04837040 Active, not recruiting - Acromegaly Clinical Trials

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly

PATHFNDR-1
Start date: May 12, 2021
Phase: Phase 3
Study type: Interventional

A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens.

NCT ID: NCT04349839 Active, not recruiting - Acromegaly Clinical Trials

ACRODAT Prospective Evaluation Study

Start date: January 15, 2020
Phase:
Study type: Observational

ACRODAT® is a new software medical device developed by a group of acromegaly experts to help practising endocrinologists assess disease activity in patients with acromegaly. It uses 5 key parameters (IGF-I level, tumour status, comorbidities, symptoms and Quality of life) to evaluate the patient's health status. The purpose of this post marketing surveillance study is to prospectively evaluate whether patients monitored by ACRODAT® with appropriate clinical decisions based on disease activity status will benefit from improved treatment outcomes both in the short and in the long term.

NCT ID: NCT04261712 Active, not recruiting - Acromegaly Clinical Trials

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

Start date: January 29, 2019
Phase: Phase 2
Study type: Interventional

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

NCT ID: NCT04125836 Active, not recruiting - Acromegaly Clinical Trials

A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly

Start date: October 10, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to assess the long-term safety and efficacy of CAM2029 in patients with acromegaly. Patients will be administered CAM2029 subcutaneously once monthly during 12 months. Patients fulfilling trial NCT04076462 will be offered to continue with open-label treatment week 24-52 in this trial. Patients completing the main part of the trial will be offered 52 weeks continued open-label treatment in an extension part.

NCT ID: NCT03252353 Active, not recruiting - Acromegaly Clinical Trials

Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly

OPTIMAL
Start date: September 1, 2017
Phase: Phase 3
Study type: Interventional

Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated maintenance of biochemical response up to 13 months in the majority of patients with acromegaly previously managed with somatostatin analog injections (reference below).

NCT ID: NCT03043586 Active, not recruiting - Acromegaly Clinical Trials

Treatment Patterns and Treatment Outcomes for Acromegaly

Start date: December 2016
Phase:
Study type: Observational

This is a human, prospective and retrospective, single-center study of patients who have undergone treatment for acromegaly in New York City since 1981. The project will characterize, among other factors, the treatment methods received by patients, who administered the treatments and the success of this therapy in terms of biochemical control.

NCT ID: NCT02668172 Active, not recruiting - Acromegaly Clinical Trials

Pasireotide LAR and Pegvisomant Study in Acromegaly

PAPE
Start date: August 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.

NCT ID: NCT02092129 Active, not recruiting - Surgery Clinical Trials

Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.

Start date: September 2013
Phase: N/A
Study type: Observational

Acromegaly is frequently associated with impaired glucose tolerance and diabetes. We hypothesise that pituitary histopathology and plasma hyperprolactinaemia could have prognostic value in predicting the risk of glucose metabolic disturbances in acromegalic patients. The aim of this study is to examine glucose metabolic outcome in acromegalic patients with and without histologically verified prolactin and growth hormone (GH) co-secreting adenomas. The study population include 79 patients who have all undergone surgical treatment for acromegaly.